A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above

PHASE1RecruitingINTERVENTIONAL

Enrollment

240

Participants

Timeline

Start Date

November 11, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL

Bivalent RSV Vaccine (IN006)

Formulation for injection

BIOLOGICAL

Placebo

0.9% sodium chloride (normal saline) injection

Trial Locations (2)

RECRUITING

Huashan Hospital Affiliated to Fudan University, Shanghai

RECRUITING

Anning First People's Hospital, Kunming

All Listed Sponsors

lead

Shenzhen Shenxin Biotechnology Co., Ltd

INDUSTRY